A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

被引:8
|
作者
Laurens, Matthew B. [1 ]
Sirima, Sodiomon B. [2 ]
Rotrosen, Elizabeth T. [1 ,4 ]
Siribie, Mohamadou [2 ]
Tiono, Alfred [2 ]
Ouedraogo, Alphonse [2 ]
Liang, Yuanyuan [3 ]
Jamka, Leslie P. [1 ]
Kotloff, Karen L. [1 ]
Neuzil, Kathleen M. [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St Room 480, Baltimore, MD 21201 USA
[2] Grp Rech Act Sante, Ouagadougou, Burkina Faso
[3] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[4] Boston Univ, Sch Med, Boston, MA 02215 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
child; typhoid-paratyphoid vaccines; Burkina Faso; immunogenicity; conjugate; ACELLULAR PERTUSSIS-VACCINE; ENTERICA SEROVAR TYPHI; SUB-SAHARAN AFRICA; IMMUNE-RESPONSE; SALMONELLA; MULTICENTER;
D O I
10.1093/cid/ciy1104
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533. The World Health Organization recently prequalified a single-dose, typhoid conjugate vaccine for children as young as 6 months of age. A randomized, controlled clinical trial will assess the safety and immunogenicity of co-administration with routine childhood vaccines in Burkina Faso.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
  • [21] Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials
    Liu, Jiankai
    Huang, Baoying
    Li, Guifan
    Huang, Tao
    Wang, Danni
    Zhang, Li
    Deng, Yao
    Chang, Xianyun
    Liu, Yafei
    Li, Weiqi
    Zhang, Siyuan
    Huang, Weijin
    Tan, Wenjie
    Gao, Lidong
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (12) : 1136 - 1142
  • [22] Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1-3 years old children: a double-blind, randomized phase III trial
    Huang, Lili
    Chen, Zhen
    Hu, Yuansheng
    Xie, Zhiqiang
    Qiu, Ping
    Zhu, Lang
    Bao, Manli
    Quan, Yaru
    Zeng, Ji
    Wang, Yanxia
    Cui, Xiaoyu
    Yuan, Liyong
    Xia, Shengli
    Meng, Fanhong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 822 - 827
  • [23] Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial
    Mohazzab, Arash
    Mehrabadi, Mohammad Hossein Fallah
    Es-haghi, Ali
    Kalantari, Saeed
    Mokhberalsafa, Ladan
    Setarehdan, Seyed Amin
    Sadeghi, Fariba
    Mokarram, Ali Rezaei
    Moradi, Monireh Haji
    Razaz, Seyad Hossein
    Taghdiri, Maryam
    Ansarifar, Akram
    Lot, Mohsen
    Khorasani, Akbar
    Nofeli, Mojtaba
    Masoumi, Safdar
    Boluki, Zahra
    Erfanpoor, Saeed
    Amiri, Fahimeh Bagheri
    Filsoof, Sara
    Mohseni, Vahideh
    Esmailzadehha, Neda
    Safari, Shiva
    Shahsavan, Masoumeh
    Bayazidi, Shnoo
    Derakhshani, Maryam Raghami
    Rabiee, Mohammad Hasan
    Golmoradi-Zadeh, Rezvan
    Khodadoost, Behnam
    Solaymani-Dodaran, Masoud
    Banihashemi, Seyed Reza
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (12) : 3012 - 3021
  • [24] Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial
    Zhang, Lifen
    Gao, Fan
    Zeng, Gang
    Yang, Haitao
    Zhu, Taotao
    Yang, Shuangmin
    Meng, Xing
    Mao, Qunying
    Liu, Xiaoqiang
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (04) : 440 - 447
  • [25] Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
    Eberhardson, Michael
    Hall, Stephen
    Papp, Kim A.
    Sterling, Tina M.
    Stek, Jon E.
    Pang, Lei
    Zhao, Yanli
    Parrino, Janie
    Popmihajlov, Zoran
    CLINICAL INFECTIOUS DISEASES, 2017, 65 (07) : 1174 - 1182
  • [26] Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Liu, Jiankai
    Huang, Baoying
    Li, Guifan
    Chang, Xianyun
    Liu, Yafei
    Chu, Kai
    Hu, Jialei
    Deng, Yao
    Zhu, Dandan
    Wu, Jingliang
    Zhang, Li
    Wang, Meng
    Huang, Weijin
    Pan, Hongxing
    Tan, Wenjie
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (10) : 1701 - 1709
  • [27] Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial
    Shin, Jonghoon
    Teeratakulpisarn, Jamaree
    Puthanakit, Thanyawee
    Theerawit, Tuangtip
    Ryu, Ji Hwa
    Shin, Jinhwan
    Lee, Seulgi
    Lee, Hayoung
    An, Kyungjun
    Kim, Hun
    CLINICAL AND EXPERIMENTAL PEDIATRICS, 2020, 63 (07) : 265 - 271
  • [28] Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial
    Lopez, Pio
    Lopez-Medina, Eduardo
    Saez-Llorens, Xavier
    deAntonio, Rodrigo
    Masuda, Taisei
    Mendelman, Paul M.
    Sherwood, James
    Baehner, Frank
    Borkowski, Astrid
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [29] Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Population Aged 3 Years and Older in Chile and the Philippines: A Phase 3, Non-Inferiority, Double-Blind, Randomized Controlled Clinical Trial
    Yang, Wanqi
    Gonzalez, Pablo A.
    Xin, Qianqian
    De Los Reyes, Mari Rose
    Villalobos, Ralph Elvi
    Borja-Tabora, Charissa Fay Corazon
    Bermal, Nancy Nazaire
    Kalergis, Alexis M.
    Yu, Dan
    Wu, Wenbin
    Bueno, Susan M.
    Huo, Liqun
    Calvo, Mario
    Zeng, Gang
    Li, Jing
    VACCINES, 2024, 12 (08)
  • [30] Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial
    Wang, Shilei
    Wang, Yanxia
    Chen, Dandan
    Xu, Wenting
    Duan, Peng
    Ji, Wei
    Liu, Weijun
    Huang, Weijin
    Wu, Bing
    Chai, Wenqing
    Zhao, Chenyan
    Yang, Yongli
    Luo, Jian
    Zhao, Dongyang
    Li, Xiuling
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)